<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title></title></head><body><div><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:Verdana; font-size:10pt">&#xa0;</span></p><p style="margin:0pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Written evidence submitted by </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">the Medical Research Council (BTO0027)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Introduction</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; padding-left:8.05pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The Medical Research Council (MRC) is one of the main agencies through which the UK Government supports medical and clinical research. For </span><span style="font-family:'Times New Roman'; font-size:11pt">over</span><span style="font-family:'Times New Roman'; font-size:11pt"> 100 years, the MRC has </span><span style="font-family:'Times New Roman'; font-size:11pt">worked to improve</span><span style="font-family:'Times New Roman'; font-size:11pt"> the health of people in the UK and around the world by supporting the highest quality science. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">We fund across the biomedical research spectrum from fundamental laboratory-based science to clinical trials and population and public health research. Through rigorous peer review, we support the highest quality internationally competitive research. We work </span><span style="font-family:'Times New Roman'; font-size:11pt">closely with the </span><span style="font-family:'Times New Roman'; font-size:11pt">Research Council’</span><span style="font-family:'Times New Roman'; font-size:11pt">s, the UK’s</span><span style="font-family:'Times New Roman'; font-size:11pt"> Health Departments, the NHS, medical research charities</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span><span style="font-family:'Times New Roman'; font-size:11pt">industry</span><span style="font-family:'Times New Roman'; font-size:11pt"> and other partners to deliver our mission</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span></li></ol><p style="margin:0pt 0pt 0pt 21.3pt; text-align:justify; text-indent:-21.3pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="2" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 13.25pt; padding-left:8.05pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">The MRC receives ‘grant-in-aid’ funding from Pa</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">rliament through the Department of </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Business, Innovation and Skills</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> (BIS)</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">. The MRC is independent of Government in the choice of which research to support and aims to provide a broadly balanced yet responsive portfolio, ensuring that research reflects changing health needs. In 2012/13 the MRC</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">’s spend on research was </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">£767 Million.</span></li></ol><p style="margin:0pt 0pt 0pt 21.3pt; text-align:justify; text-indent:-21.3pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="3" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; padding-left:8.05pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">We welcome the opportunity to provide evidence to the Committee and have focused on the questions that are most relevant to the remit and expertise</span><span style="font-family:'Times New Roman'; font-size:11pt"> of the MRC</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">  This response details the contribution of MRC funded research to the evidence base in this area, and more broadly to the understanding of the public health risks posed by variant Creutzfeldt-Jakob Disease (vCJD).</span></li></ol><p style="margin:0pt 0pt 0pt 21.3pt; text-align:justify; text-indent:-21.3pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="4" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; padding-left:8.05pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In addition to the public sector funding of prion-related research and support for its translation into practice, policy, or commercial products, </span><span style="font-family:'Times New Roman'; font-size:11pt">the Committee should be aware </span><span style="font-family:'Times New Roman'; font-size:11pt">that MRC is a minority shareholder in D-Gen, a small company which works towards  commercialisation of science from the MRC Prion Unit</span><span style="font-family:'Times New Roman'; font-size:11pt">, one of the routes to translate such research into clinical care</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li></ol><p style="margin:0pt 0pt 0pt 35.5pt; text-align:justify; text-indent:-35.5pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 35.5pt; text-align:justify; text-indent:-35.5pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Responses to the questions of the Science and Technology Committee</span><span style="font-family:Calibri; font-size:12pt; font-variant:small-caps"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:normal">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:normal">Are UK policies governing who can donate blood and blood products, tissues and organs sufficiently evidence-based? Is NHS Blood and Transplant overly restrictive about who can donate, or should greater precautions be taken to further reduce risk?</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span></p><ol start="5" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 13.25pt; padding-left:8.05pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">In research relating to development of tests, such as </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">diagnostic test </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">for prion diseases, the role of the MRC is to support discovery science, its translation into test development and the early assessment of such tests. Evaluation and adoption are supported by the UK Health Departments and the NHS. </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span></p><ol start="6" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">CJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> (</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Creutzfeldt-Jakob disease) is a prion disease and is </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">a </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">form of TSE</span><span style="font-family:'Times New Roman'; font-size:11pt"> (</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">transmissible spongiform encephalopathy) that occurs in humans. Variant CJD (vCJD) was first identified in 1996 and the evidence indicates that it originated through the consumption by humans of meat or meat products from BSE-infected cattle.  </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">vCJD accounts for less than 1% of cases of </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">CJD </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">which </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">can also occur as sporadic (sCJD). sCJD is the commonest form of the disease and has no known cause, it is not considered to be related to BSE</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> and</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> occurs world-wide at a rate of between 0.5 and 1.5 cases per million inhabitants per year</span><a name="_ftnref1"></a><a href="#_ftn1">[1]</a><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">.</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">The average age of onset of </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">sCJD </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">is</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> 65.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span></p><ol start="7" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">By mid 2006, 156 people in the UK had definitely or probably died from vCJD. By July 2012 the ACDP (Advisory Committee on Dangerous Pathogens) TSE Risk Assessment Subgroup had reported that a further 20 people in the UK had died from vCJD (bringing the total to</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> 176 </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">patients).</span><a name="_ftnref2"></a><a href="#_ftn2">[2]</a><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Patients have typically been young, with a median age of about 28 years at onset of symptoms.  This compare</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">s</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> with over 220 cases reported world-wide </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">to</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> the same date, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">with</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> prevalence of vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> being </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">far </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">greater</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> in the UK. The annual peak in both deaths and diagnoses in the UK was in 2000. In February 2013, the DH</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">advised that there had been 176 deaths from known cases in the UK, with only one new onset case (in October2010)</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">,</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> who has since died</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span></p><ol start="8" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 13.25pt; padding-left:8.05pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">In 1998, in recognition of the urgent need to understand the basis of TSE transmission by prion proteins, the MRC set up a Unit focused principally on TSE research – the MRC Prion Unit, now at University College London and directed by Professor John Collinge. The Unit was established to be an international centre of excellence and to bridge the interface between basic science and clinical research.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Two key goals have been the development of a reliable diagnostic test to identify the earliest possible stage of infection and </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">the development of</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> new treatments and preventive measures for CJD</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> (both sporadic and variant)</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">.  The MRC also supports research in universities and hospitals across the UK, to increase understanding of CJD and to develop ways of diagnosing and treating this rare but fatal condition.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="9" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">From 2008/09 to 2012/13 the MRC spent a total of £61m on research related to prion disease within a portfolio of £214m on research into all neurodegenerative diseases (inclusive of spend on prion diseases). A large proportion of the research we support in this area relates to the core work of the MRC Prion Unit</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">at a level of approximately £6m per annum for core Unit programmes. The portfolio also includes research at the MRC Toxicology Unit (Leicester), the MRC Biostatistics Unit (Cambridge) and current grant funding at UCL, Leeds and Edinburgh, and supplementary funding for specific projects at the Prion Unit.  This research spans basic biological studies through to clinical research and epidemiology. In addition to core programme support, the MRC Prion Unit has received significant additional funding in the form of strategic awards for translational work on development of blood tests and therapies for CJD.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span></p><ol start="10" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">The </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">MRC recognises that developing drug treatments for prion disease will not easily attract strong private sector investment, because of the high degree of scientific challenge and risk, and the low prevalence.  Therefore, even before developing its current translational funding schemes, the MRC decided to take the risk of investing in therapy development for prion disease.  </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Details</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> of this investment are</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">provided below</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="11" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">The MRC provided a strategic award of £7.9m to the Unit for a programme seeking to develop immunotherapy for prion disease – a £4.7m award in 2007 supplemented by £3.2m in 2010. The purpose of the programme was to develop mouse humanised antibodies as a therapy</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">for prion disease, with staged funding based on independent reviews of progress and prospects of success.  A £12.3m</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">,</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> 55-month proposal to </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">progress </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">the approaches developed thus far into </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">phase I and II</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">clinical trial</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">s</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> was declined on scientific grounds by the MRC Developmental Pathway Funding Scheme </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">(DFPS) </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Panel in May 2013. Following this</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> decision</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">, the MRC set up an independent panel of experts to advise the Chief Executive on whether, and if so how, to pursue this line of work further. As a result, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Professor </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Collinge has been asked </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">to </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">prepare a research plan to understand the </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">biological </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">effects of this immunotherapy in humans with prion disease</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> predicated on a phase I clinical trial</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">. The Unit is also working on a separate project seeking to develop a different, drug-based approach to therapy; a proposal for further funding to take this to the next stage of development has been resubmitted </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">to the MRC DPFS Panel </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">for consideration following feedback on an initially declined proposal. </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span></p><ol start="12" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">The MRC also funds studies into therapeutic interventions in prion disease at the </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Council’s </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Toxicology Unit. Recently published data from th</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">at </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Unit show that a highly novel experimental approach, using a small molecule delivered</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">orally can delay disease progression in mice. Although the drug has too many side effects to allow it to be used experimentally in humans, work is ongoing to find agents with similar effects that might safely be used in humans.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span></p><ol start="13" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">The latest data on estimated prevalence of presence of abnormal prion protein in the UK population from appendix samples is 1 in 2000 people. This information was from analysis of appendix samples collected during surgery on patients born between 1941 and 1985 (ACDP TSE Risk Assessment Subgroup, July 2012). The hypothesis is that this prevalence is linked to the epidemic of BSE in cattle in Britain. In order to further investigate the link to the BSE epidemic, a further study has been commissioned by the DH to test appendix samples archived prior to the BSE outbreak which began in the UK in the 1980s and appendix samples from those born in 1996 or later (when measures to protect the food chain were in place), and thus in both cases individuals would be very unlikely to have consumed products from animals with BSE. The study is due to report in 2015.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span></p><ol start="14" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">There are important questions for public health in relation to the implications of the prevalence rate estimated from appendectomy studies. These include consideration as to the significance:</span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 54pt; text-align:justify; text-indent:-18pt"><span style="font-family:Verdana; font-size:11pt">•</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">For the health of individuals who carry abnormal prion proteins but have no symptoms, the lifetime risk of development of clinical vCJD in these people is unknown</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">.</span></p><p style="margin:0pt 0pt 0pt 72pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 54pt; text-align:justify; text-indent:-18pt"><span style="font-family:Verdana; font-size:11pt">•</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">For the recipients of donated blood or blood products or organs who may be</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> at risk of</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> infect</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">ion</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> if they receive blood or tissue from infected, but asymptomatic and undiagnosed individuals</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">It remains the case that the risk of transmission by blood or blood products or organs from infected but asymptomatic donors is unknown and there are, as yet, no effective treatments to remove prion infection from the blood or indeed for prion disease itself.  </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span></p><ol start="15" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Development of an effective test for detecting the presence of abnormal prion proteins in urine or blood would have benefit both for diagnosis in patients and for screening blood prior to its entering the transfusion service. In the following points we briefly summarise some of the considerations for development of effective screening tests.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span></p><ol start="16" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Screening is a process of identifying apparently healthy people who may be at increased risk of a disease or condition. It carries with it an implication of benefit for the individual and/or the population as a whole. </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span></p><ol start="17" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Acknowledged criteria are available for the introduction of a screening test into the UK health services to be applied to all or a subset of the UK population</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">.</span><a name="_ftnref3"></a><a href="#_ftn3">[3]</a><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> A clinical diagnostic test </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">may have different requirements</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> to a screening test as it </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">might be applied, for example, to help to confirm diagnosis in persons attending a neurological clinic with a suspected diagnosis of prion disease, as part of a panel of clinical assessment tools. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Screening tests, by contrast, are generally applied across a population that includes those with and without the condition and in the absence of detailed clinical information about those tested. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Quality criteria for tests for vCJD are set out in the EU Medical Devices Directive</span><a name="_ftnref4"></a><a href="#_ftn4">[4]</a><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">, These are based on the minimal quality requirements equivalent to other devices used for blood testing. MHRA guidance</span><a name="_ftnref5"></a><a href="#_ftn5">[5]</a><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> is also available on </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">application of </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">the Directive in the UK.  These recommend that </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">the </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">diagnostic sensitivity of tests </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">for vCJD </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">should exceed 90%.</span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span></p><ol start="18" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">There is an inherent difference in requirements for a screening</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> or diagnostic</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> test to detect levels of an agent in the blood in the case of an individual or for population protection compared with a test that would be used in the NHS to guarantee the safety of blood testing. To be used routinely in blood </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">donor screening</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">, a test to detect the presence of vCJD would need to be sufficiently reliable</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> in excluding positive samples</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> to mean that the existing protective measures are no longer necessary and can be removed.  Such reliability would require very high standards of accuracy.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span></p><ol start="19" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">In any screening programme there can be false positive test results (people with a positive screening test who do not actually have or carry the condition) and false negative results (people who have a negative screening result but do actually have or carry the condition), the goal being to minimise both. The former is referred to as the specificity of the test, the latter as the sensitivity.</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Thus specificity is a measure of test performance. High specificity means that there are as few false positives as possible. High sensitivity means that the test rarely fails to detect genuine disease. </span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span></p><ol start="20" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">The ethics of screening tests and their introduction must also be carefully considered. Screening is often used in apparently healthy people and may allow them to make informed choices about their health, if information from the screening is provided. If blood collected from donors were to be routinely screened for prion disease there could be an obligation to inform affected individuals. However, it is </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">not known </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">what proportion of people who carry prion proteins in their blood will go on to develop vCJD during their lifetime, and currently there are no effective interventions or treatments and so the individual benefit is very limited, if not negative.  </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Should a sufficiently sensitive and reliable test (or battery of tests) become available in the future</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">, it should be considered whether vCJD testing to establish population prevalence or to screen for the presence of vCJD in blood donations should be anonymous (</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">i.e.</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> without feedback to individuals), as happened </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">in some clinical settings for prevalence of</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> HIV</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">.</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span></p><ol start="21" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">The MRC Prion Unit published data on a new blood test for CJD in February 2011 (Lancet 377: 487-493). The prototype test was able to detect blood spiked with a dilution of vCJD to within one part per ten billion - 100,000 times more sensitive than any other method developed so far. A follow-up phase of blood test work was funded by MRC in 2011 (£200k plus supplementary funding from the Unit’s own budget) to use the test on blood from 5000 US blood donors assumed to have had minimal exposure to BSE (</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">i.e.</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> used as control samples) to assess the specificity of the assay.  The study was both to develop the test as a screening tool as well as to provide early information on prevalence. This study showed that there were no false positives. The published specificity of this test is therefore excellent</span><span style="font-family:'Times New Roman'; font-size:11pt"> (</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">100%, with 95% CI: 99.93-100%); however the sensitivity as presented in the report to the MRC was only 71% (CI: 48-89%). The level of sensitivity was determined by testing samples from known CJD patients, individuals who already had clinical symptoms.  A follow-on proposal for a much larger study of the same test on the UK population based on the UK Biobank cohort compared with unexposed US veterans was declined by the MRC in March 2013.</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> This proposal aimed to further develop the blood test towards a screening test for blood donors and to provide further information on UK prevalence of vCJD in blood</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span></p><ol start="22" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">This low level of sensitivity was one reason for the follow-on proposal not being supported by MRC. The Unit was advised to consider ways to improve the test sensitivity to provide greater confidence of identification of infected people, in order to make the test more accurate for prevalence studies and more attractive for development into a screening test. The proposal was subject to rigorous peer review with expertise in the relevant areas of science and was considered by external independent reviewers with the final decision taken by the MRC’s Strategy </span><a href="http://www.mrc.ac.uk/About/Structure/Strategyboard/Keyfacts/index.htm"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">Board</span></a><a name="_ftnref6"></a><a href="#_ftn6">[6]</a><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span></p><ol start="23" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">There are other tests also in development based on different technologies and it may be that a combination approach would be the most effective approach for screening and confirmatory testing. The Unit’s test relies on a solid state binding matrix.  Other tests based on protein-misfolding cyclic amplification (PMCA), Quacking Induced Conversion (QuIC) or other methods are being </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">developed </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">in Europe and USA.</span><a name="_ftnref7"></a><a href="#_ftn7">[7]</a><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">  </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span></p><ol start="24" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">None of these tests is, as far as we are aware, yet ready for population screening, or able to offer a reliable way of guaranteeing the safety of transfused blood.  A confounding issue may be that the properties of prion protein in blood may differ from </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">its’ </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">properties in brain. The recent paper cited in the previous paragraph</span><span style="font-family:'Times New Roman'; font-size:7.33pt; font-weight:normal; vertical-align:super">6</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> expands on these issues and provides an update on these latest advances for the detection of misfolded prion protein in body fluids.</span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:normal">What are the strengths and weaknesses of NHS Blood and Transplant’s strategy, “Taking Organ Transplantation to 2020”? What further changes could be made to safely increase the supply of blood and blood products, tissues and organs?</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:normal">&#xa0;</span></p><ol start="25" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">The strategy recognises the need for research and development (p27). The MRC has had previous discussions with other organisations, such as the HPA, DH (England) and the NHSBTS about the research base in this area. It is our understanding that the ACDP will coordinate a further discussion on state of development of blood tests in the early part of 2014, drawing together expertise from other relevant Advisory Committees.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">January 2014</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">&#xa0;</span></p><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:center"><span style="font-family:Verdana; font-size:10pt">&#xa0;</span></p><p style="font-size:10pt; line-height:115%; margin:0pt 18pt 10pt 0pt"><span style="font-family:Verdana; font-size:10pt">&#xa0;</span></p></div><hr style="width:33%; height:1px; text-align:left" /><p style="margin:0pt"><a name="_ftn1"></a><a href="#_ftnref1">[1]</a><span style="font-family:Verdana; font-size:8pt"> </span><a href="http://www.who.int/zoonoses/diseases/Creutzfeldt.pdf"><span style="color:#0000ff; font-family:Verdana; font-size:8pt; text-decoration:underline">http://www.who.int/zoonoses/diseases/Creutzfeldt.pdf</span></a></p><p style="margin:0pt"><a name="_ftn2"></a><a href="#_ftnref2">[2]</a><span style="font-family:Verdana; font-size:8pt"> vCJD and transfusion of blood components: an updated risk assessment: Bennett P and Daraktchiev M, DH Health Protection Analytical team, February 14</span><span style="font-family:Verdana; font-size:5.33pt; vertical-align:super">th</span><span style="font-family:Verdana; font-size:8pt"> 2013</span></p><p style="margin:0pt"><a name="_ftn3"></a><a href="#_ftnref3">[3]</a><span style="font-family:Verdana; font-size:8pt"> PHE UK National Screening Committee Screening Portal: </span><a href="http://www.screening.nhs.uk/criteria"><span style="color:#0000ff; font-family:Verdana; font-size:8pt; text-decoration:underline">http://www.screening.nhs.uk/criteria</span></a></p><p style="margin:0pt"><a name="_ftn4"></a><a href="#_ftnref4">[4]</a><span style="font-family:Verdana; font-size:8pt"> EC Guideline for the CE marking of blood based in vitro diagnostic medical devices for vCJD based on detection of abnormal PrP – January 2012</span></p><p style="margin:0pt"><a name="_ftn5"></a><a href="#_ftnref5">[5]</a><span style="font-family:Verdana; font-size:8pt"> MHRA Guidance on the In Vitro Diagnostic Medical Devices Directive 98/79/EC – August 2013</span></p><p style="margin:0pt"><a name="_ftn6"></a><a href="#_ftnref6">[6]</a><span style="font-family:Verdana; font-size:8pt"> </span><span style="font-family:Verdana; font-size:8pt">The board is chaired by the Chief Executive. Membership consists of chairs of the four research boards (Infections and Immunity, Molecular and Cellular Medicine, Neurosciences and Mental Health, Population and Systems Medicine), chairs of the four overview groups (Global Health, Population Health Sciences, Training and Careers, Translational Research), a director of an MRC institute, an extramural representative, the Chief Science Officer and the Deputy CEO/Director of Strategy.</span></p><p style="margin:0pt"><a name="_ftn7"></a><a href="#_ftnref7">[7]</a><span style="font-family:Verdana; font-size:8pt"> Properzi F and Pocchiari M (2013). Identification of Misfolded Proteins in Body Fluids for the Diagnosis of Prion Diseases. Int J Cell Biol Volume 2013 (2013) </span><a href="http://www.hindawi.com/journals/ijcb/2013/839329/"><span style="color:#0000ff; font-family:Verdana; font-size:8pt; text-decoration:underline">http://www.hindawi.com/journals/ijcb/2013/839329/</span></a></p></body></html>